BioPharma Terug naar discussie overzicht

PR GTC 20/9/05

1. [verwijderd] 20 september 2005 14:40

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   
   www.nasdaq.com/aspxcontent/NewsStory....
   
   biz.yahoo.com/prnews/050920/netu008.h...
   
   Mvg
   
   Jkpunt
2. frederic_knight 20 september 2005 14:42

   auteur info

   • frederic_knight

     Lid sinds: 04 okt 2004

     Laatste bezoek: 11 apr 2023

   • Aanbevelingen

     Ontvangen: 14

     Gegeven: 12

   •    Aantal posts: 64

   GTC BIOTHERAPEUTICS ENTERS AGREEMENT FOR FURTHER CLINICAL PRODUCTION OF MM-093 FOR MERRIMACK PHARMACEUTICALS
   
   FRAMINGHAM, MA – September 20, 2005 -- GTC Biotherapeutics, Inc. ("GTC", Nasdaq: GTCB) announced today that it has entered into an agreement for further production of MM-093 for Merrimack Pharmaceuticals, Inc. MM-093, Merrimack’s lead clinical product, is a recombinant version of human alpha-fetoprotein. Merrimack is conducting a Phase II study of MM-093 in patients with rheumatoid arthritis and is planning additional clinical studies.
   
   
   “We are pleased to continue to support Merrimack’s supply needs for their clinical studies of MM-093,” stated Gregory Liposky, GTC’s Senior Vice President of Operations. “GTC’s technology is a cost-effective production method for recombinant proteins and is well suited for the production of Merrimack’s human alpha-fetoprotein.”
   
   
   
   About Merrimack Pharmaceuticals
   
   Merrimack Pharmaceuticals, Inc. is a biotechnology company focused on the discovery and development of novel treatments for diseases in the areas of autoimmune disease and cancer. Its lead compound, MM-093, is currently in clinical development to treat patients with rheumatoid arthritis. MM-093 is an investigational drug and has not been approved by the U.S. Food and Drug Administration or any international regulatory agency. The company's proprietary Network Biology discovery platform, developed with the help of leading scientists from MIT and Harvard, enables the high throughput profiling of protein networks as a basis for improved validation, lead identification and speed in the development of innovative, effective and safe therapeutics.
   
   Merrimack is a privately held company based in Cambridge, Massachusetts. For additional information, please visit www.merrimackpharma.com.
   
   About GTC Biotherapeutics, Inc.
   
   GTC Biotherapeutics is a leader in the development, production, and commercialization of therapeutic proteins through transgenic animal technology. GTC currently has five products in its internal pipeline and a portfolio of external program production opportunities. GTC's lead program is ATryn®, its recombinant form of human antithrombin. A Market Authorization Application is under review by the European Medicines Agency for the use of ATryn® in patients with a hereditary antithrombin deficiency. In addition to the lead ATryn® program, GTC is developing a recombinant human alpha-1 antitrypsin, a recombinant human albumin, a malaria vaccine, and a CD137 antibody to stimulate the immune system as a potential treatment for solid tumors. In its external programs, GTC's technology is used to develop transgenic production of its partners' proprietary products, including both large-volume protein therapeutics as well as products that are difficult to produce in significant quantities from conventional recombinant production systems. Additional information is available on the GTC web site, www.gtc-bio.com.
   
   
   
   This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including without limitation statements regarding continuing clinical studies of MM-093 and GTC’s role in producing further supplies. Such forward-looking statements are subject to a number of risks, uncertainties and other factors that could cause actual results to differ materially from future results expressed or implied by such statements. Factors that may cause such differences include, but are not limited to, the risks and uncertainties discussed in GTC's most recent Annual Report on Form 10-K and its other periodic reports as filed with the Securities and Exchange Commission, including the uncertainties associated with conducting clinical studies, and the risks and uncertainties associated with dependence upon the actions of partners. GTC cautions investors not to place undue reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this document, and GTC undertakes no obligation to update or revise the statements, except as may be required by law.
   
   
   
   CONTACT:
   GTC Biotherapeutics, Inc.
   Thomas E. Newberry
   Vice President, Corporate Communications
   US (508) 370-5374
   
   
   
   Feinstein Kean Healthcare for GTC Biotherapeutics, Inc.
   Francesca DeVellis
   US (617) 577-8110
   
   If you wish to be removed from this distribution list, please reply to this email with "REMOVE" in the subject line.
   
   
3. [verwijderd] 20 september 2005 15:07

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Kan iemand de waarde van dit PB inschatten ?
4. gvanmaarsum 20 september 2005 15:12

   auteur info

   • gvanmaarsum

     Lid sinds: 01 jan 2000

     Laatste bezoek: 08 feb 2025

   • Aanbevelingen

     Ontvangen: 426

     Gegeven: 104

   •    Aantal posts: 857

   quote:

   killer_forehand schreef:

   Hebben klein maandje geleden ofzo ook al zo'n award gewonnen, meen ik. Koers deed toen niet zoveel.
   

   Bericht niet gelezen? Dit gaat niet om een Award.
5. [verwijderd] 20 september 2005 15:13

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Je hebt gelijk, had alleen 1e persbericht gelezen.
6. [verwijderd] 20 september 2005 15:20

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   We are pleased to continue to support Merrimack’s supply needs for their clinical studies of MM-093
   
   wil zeggen dat het gewoon over een voortgezette samenwerking gaat
   zoveel nieuws is dat niet zeker?
   Compu
   
7. [verwijderd] 20 september 2005 15:21

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   
   En ik had vergeten de eerste link te wissen want dat was reeds ook op 15/8/05 verschenen.
   
   2de leek me iets interessanter
   
   Mvg
   
   Jkpunt
   
8. spyfly 20 september 2005 15:23

   auteur info

   • spyfly

     Lid sinds: 28 jan 2002

     Laatste bezoek: 29 mei 2024

   • Aanbevelingen

     Ontvangen: 3

     Gegeven: 11

   •    Aantal posts: 476

   Pre-Market (RT-ECN): 1.24 0.07 (5.98%)
9. [verwijderd] 20 september 2005 21:28

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   
   
   biz.yahoo.com/bizj/050920/1166511.htm...
   
   mvg
   jkp.
10. [verwijderd] 20 september 2005 21:37

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    HAd ik nog nergens gelezen
    
    mvg
    JK.